Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice

Pharmacological Reports

Volumn 64, Issue 5, 2012, Pages 1066-1080

  Kruk Słomka, Marta ^a   Budzyńska, Barbara ^a   Biała, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Mecamylamine; Memory and learning; Modified elevated plus maze; Nicotine; Scopolamine; Varenicline

Indexed keywords

CHOLINERGIC RECEPTOR; MECAMYLAMINE; MUSCARINIC RECEPTOR; NICOTINE; SCOPOLAMINE; VARENICLINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; INFORMATION RETRIEVAL; LATENT PERIOD; LOCOMOTION; MEMORY CONSOLIDATION; MEMORY DISORDER; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SPATIAL MEMORY;

EID: 84873719659     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70904-0     Document Type: Article

References (77)

1. Addy NA, Nakijama A, Levin ED: Nicotinic mechanisms of memory: Effects of acute local DHßE and MLA infusions in the basolateral amygdala. Cognit Brain Res, 2003, 16, 51-57. (Pubitemid 36183540)
2. Bancroft A, Levin ED: Ventral hippocampal α4β2 nicotinic receptors and chronic nicotine effects on memory. Neuropharmacology, 2000, 39, 2770-2778.
3. Bettany JH, Levin ED: Ventral hippocampal α7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze. Pharmacol Biochem Behav, 2001, 70, 467-474. (Pubitemid 34131641)
4. Biala G, Kruk M: Cannabinoid receptor ligands suppress memory-related effects of nicotine in the elevated plus maze test in mice. Behav Brain Res, 2008, 192, 198-202.
5. Biala G, Kruk M: Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep, 2009, 61, 236-244.
6. Biala G, Staniak N: Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacol Biochem Behav, 2010, 96, 141-147.
7. Biala G, Staniak N, Budzynska B: Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn-Schmiedeberg's Arch Pharmacol, 2010, 381, 361-370.
8. Brown RW, Beale KS, Frye J: Mecamylamine blocks enhancement of reference memory but not working memory produced by post-training injection of nicotine in rats tested on the radial arm maze. Behav Brain Res, 2002, 134, 259-265. (Pubitemid 34912705)
9. Blokland A: Acetylcholine: a neurotransmitter for learning and memory? Brain Res Brain Rev, 1995, 21, 285-300.
10. Buccafusco JJ: Neuronal nicotinic receptor subtypes: Defining therapeutic targets. Mol Interv, 2004, 4, 285-295.
11. Buccafusco JJ, Jackson WJ, Terry Jr. AV, Marsh KC, Decker MW, Arneric SP: Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: A novel cholinergic channel activator for memory enhancement. Psychopharmacology, 1995, 120, 256-266.
12. Bushnell PJ: Effects of scopolamine on locomotor activity and metabolic rate in mice. Pharmacol Biochem Behav, 1987, 26, 195-198.
13. Celikyurt IK, Akar FY, Ulak G, Mutlu O, Erden F: Effects of risperidone on learning and memory in naive and MK-801-treated rats. Pharmacology, 2011, 87, 187-194.
14. Corringerr PJ, Le NN, Changeux JP: Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol, 2000, 40, 431-458.
15. Crunelle CL, Miller ML, Booij J, van den Brink W: The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review. Eur Neuropsychopharmacol, 2010, 20, 69-79.
16. 2Areceptor blockade prevents memory dysfunction caused by β-amyloid peptides but not by scopolamine or MK-801. Exp Neurol, 2008, 210, 776-781.
17. Davis JA, Kenney JW, Gould TJ: Hippocampal α4β2 nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. J Neurosci, 2007, 27, 10870-10877. (Pubitemid 47535866)
18. Deiana S, Platt B, Riedel G: The cholinergic system and spatial learning. Behav Brain Res, 2011, 221, 389-411.
19. Dutar P, Bassant MH, Senut MC, Lamour Y: The septohippocampal pathway: Structure and function of a central cholinergic system. Physiol Rev, 1995, 75, 393-427.
20. Ebert U, Kirch W: Scopolamine model of dementia: Electroencephalogram findings and cognitive performance. Eur J Clin Invest, 1998, 28, 944-949. (Pubitemid 28521587)
21. Frishman WH: Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis, 2009, 3, 287-308.
22. Gentry CL,Wilkins Jr LH, Lukas RJ: Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human α4β2- and α4β4-nicotinic acetylcholine receptors. J Pharmacol Exp Ther, 2003, 304, 206-216. (Pubitemid 36008930)
23. Glick SD, Greenstein S: Differential effects of scopolamine and mecamylamine on passive avoidance behavior. Life Sci, 1972, 11, 169-179.
24. Grottick AJ, Higgins GA: Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav Brain Res, 2000, 117, 197-208.
25. Hasselmo ME: The role of acetylcholine in learning and memory. Curr Opin Neurobiol, 2006, 16, 710-715.
26. Hefco V, Yamada K, Hefco A, Hritcu L, Tiron A, Olariu A, Nabeshima T: Effects of nicotine on memory impairment induced by blockade of muscarinic, nicotinic and dopamine D2 receptors in rats. Eur J Pharmacol, 2003, 474, 227-232. (Pubitemid 37281454)
27. Hiramatsu M, Inoue K: Improvement by low doses of nociceptin on scopolamine-induced impairment of learning and/or memory. Eur J Pharmacol, 2000, 395, 149-156. (Pubitemid 30224819)
28. Hiramatsu M, Murasawa H, Mori H, Kameyama T: Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous kappa-opioid receptor agonist. Br J Pharmacol, 1998, 123, 920-926. (Pubitemid 28085393)
29. Hogg RC, Bertrand D: Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem Pharmacol, 2007, 73, 459-468. (Pubitemid 46043572)
30. Husain M, Mehta MA: Cognitive enhancement by drugs in health and disease. Trends Cogn Sci, 2011, 15, 28-36.
31. Itoh J, Nabeshima T, Kameyama T: Utility of an elevated plus maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology, 1990, 101, 27-33. (Pubitemid 20124737)
32. Itoh J, Nabeshima T, Kameyama T: Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol, 1991, 194, 71-76.
33. James JR, Nordberg A: Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease. Behav Genet, 1995, 25, 149-159.
34. Karam-Hage M, Cinciripini PM: Pharmacotherapy for tobacco cessation: Nicotine agonists, antagonists, and partial agonists. Curr Oncol Rep, 2007, 9, 509-516. (Pubitemid 350081488)
35. Knoppman D: Pharmacothephy for Alzheimer's disease. Curr Neurol Neurosci Rep, 2001, 1, 428-432.
36. Kruk M, Tendera K, Biala G: Memory-related effects of cholinergic receptor ligands in mice as measured by the elevated plus maze test. Pharmacol Rep, 2011, 63, 1372-1382.
37. Levin ED: Nicotinic systems and cognitive function. Psychopharmacology, 1992, 108, 417-431.
38. Levin ED, Bradley A, Addy N, Sigurani N: Hippocampal α7 and α4β2 nicotinic receptors and working memory. Neuroscience, 2002, 109, 757-765. (Pubitemid 34260859)
39. Levin ED, CastonguayM, Ellison GD: Effects of the nicotinic receptor blocker mecamylamine on radial-arm maze performance in rats. Behav Neural Biol, 1987, 48, 206-212. (Pubitemid 18078550)
40. Levin ED, Kaplan S, Boardman A: Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol, 1997, 8, 236-242. (Pubitemid 27303918)
41. Levin ED, Petro A, Rezvani AH, Pollard N, Christopher NC, Strauss M, Avery J, Nicholson J, Rose JE: Nicotinic α7- or β2-containing receptor knockout: Effects on radial-arm maze learning and long-term nicotine consumption in mice. Behav Brain Res, 2009, 196, 207-213.
42. Levin ED, Rezvani AH: Nicotinic treatment for cognitive dysfunction. Curr Drug Target CNS Neurol Disord, 2002, 1, 423-431.
43. Levin ED, Rezvani AH: Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol, 2007, 74, 1182-1191. (Pubitemid 47417933)
44. Levin ED, Simon B: Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology, 1998, 138, 217-230. (Pubitemid 28365487)
45. Lippiello PM, Bencherif M, Caldwell WS, Arrington SR, Fowler KW, Lovette ME, Reeves LK: Metanicotine: A nicotinic agonist with central nervous system selectivity - In vitro and in vivo characterization. Drug Dev Res, 1996, 38, 169-176.
46. Lippiello PM, Bencherif M, Gray JA, Peters S, Grigoryan G, Hodges H, Collins AC: RJR-2403: A nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther, 1996, 279, 1422-1429. (Pubitemid 27166791)
47. Lister RG: The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 1987, 92, 180-185.
48. Livingstone PD, Srinivasan J, Kew JNC, Dawson LA, Gotti C, Moretti M, Shoaib M, Wonnacott S: α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci, 2009, 29, 539-550.
49. Marks MJ, Whiteaker P, Collins AC: Deletion of the α7, β2, or β4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. Mol Pharmacol, 2006, 70, 947-959. (Pubitemid 44268451)
50. Marubio LM., Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM et al.: Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci, 2003, 17, 1329-1337. (Pubitemid 36560833)
51. Masuoka T, Kamei C: The role of nicotinic receptors in the amelioration of cholinesterase inhibitors in scopolamine-induced memory deficits. Psychopharmacology, 2009, 206, 259-265.
52. McGurk SR, Levin ED, Butcher LL: Radial-arm maze performance in rats is impaired by a combination of nicotinic-cholinergic and D2 dopaminergic antagonist drugs. Psychopharmacology, 1989, 99, 371-373. (Pubitemid 19244117)
53. Mihalak KB, Carroll FI, Luetje CW: Varenicline is a partial agonist at α4β2 and a full agonist at a7 neuronal nicotinic receptors. Mol Pharmacol, 2006, 70, 801-805. (Pubitemid 44268437)
54. Mirza NR, Stolerman IP: The role of nicotinic and muscarinic acetylcholine receptors in attention. Psychopharmacology, 2000, 48, 243-250. (Pubitemid 30136731)
55. Miyazaki S, Imaizumi M, Onodera K: Ameliorating effects of histidine on scopolamine-induced learning deficits using an elevated plus-maze test in mice. Life Sci, 1995, 56, 1563-1570.
56. Moran PM: Scopolamine deficits in negative patterning discrimination: evidence for a role of the central cholinergic system in retention but not acquisition of nonspatial configural association learning. Behav Brain Res, 1992, 48, 187-197.
57. Papke RL, Sanberg PR, Shytle RD: Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther, 2001, 297, 646-656. (Pubitemid 32377996)
58. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC, Frey JM et al.: Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry, 2009, 65, 144-149.
59. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL: Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther, 2001, 92, 89-108. (Pubitemid 34251128)
60. Pitsikas N, Rigamonti AE, Cella SG, Locatelli V, Sala M, Muller EE: Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat. Eur J Pharmacol, 2001, 426, 193-200. (Pubitemid 32781777)
61. Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA: Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology, 1999, 142, 334-342. (Pubitemid 29187621)
62. Puma C, Deschaux O, Molimard R, Bizot JC: Nicotine improves memory in an object recognition task in rats. Eur Neuropsychopharmacol, 1999, 9, 323-327. (Pubitemid 29253784)
63. Raybuck JD, Portugal GS, Lerman C, Gould TJ: Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice behavioral. Neuroscience, 2008, 122, 1166-1171.
64. Rezvani AH, Bushnell PJ, Levin ED: Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats. Psychopharmacology, 2002, 164, 369-375. (Pubitemid 35435712)
65. Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P: A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res, 1991, 547, 67-170.
66. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y et al.: Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology, 2007, 52, 985-994. (Pubitemid 46227486)
67. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE: Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation. Trends Pharmacol Sci, 2007, 28, 316-325. (Pubitemid 47016686)
68. Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE et al.: Preclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol, 2009, 78, 813-824.
69. Schon K, Atri A, Hasselmo ME, Tricarico MD, LoPresti ML, Stern CE: Scopolamine reduces persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans. J Neurosci, 2005, 25, 9112-9123. (Pubitemid 41500819)
70. Serafim KR, Kishi M, Canto-de-Souza A, Mattioli R: L-histidine provokes a state-dependent memory retrieval deficit in mice re-exposed to the elevated plus-maze. Braz J Med Biol Res, 2010, 43, 100-106.
71. Sharma AC, Kulkarni SK: Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiatry, 1992, 16, 117-125.
72. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA, 2007, 104, 12518-12523. (Pubitemid 47206170)
73. Voss B, Thienel R, Reske M, Habel U, Kircher T: Cognitive performance and cholinergic transmission: Influence of muscarinic and nicotinic receptor blockade. Eur Arch Psychiatry Clin Neurosci, 2009, 260, 106-110.
74. West R, Baker CL, Cappelleri JC, Bushmakin AG: Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology, 2008, 197, 371-377.
75. Yin R, French ED: A comparison of the effects of nicotine on dopamine and non-dopamine neurons in the rat ventral tegmental area: An in vitro electrophysiological study. Brain Res Bull, 2000, 51, 507-514. (Pubitemid 30176095)
76. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C, Finlayson K, Sharkey J: Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol, 2007, 17, 145-155. (Pubitemid 44802833)
77. Yu J, Huang YW, Chen Z: Improved alternative electrostimulus Y-maze for evaluating the spatial memory of rats. J Zhejiang Univ Sci, 2003, 32, 121-125.